In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4+ T cell levels in humanized mice

Journal of Immunology

Volumn 190, Issue 1, 2013, Pages 211-219

  Palmer, Brent E ^a   Neff, C Preston ^b   LeCureux, Jonathan ^b   Ehler, Angelica ^a   DSouza, Michelle ^a   Remling Mulder, Leila ^b   Korman, Alan J ^c   Fontenot, Andrew P ^a   Akkina, Ramesh ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c Biologics Discovery California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE COURSE; FLOW CYTOMETRY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VIVO STUDY; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS LOAD;

ANIMALS; ANTIGENS, CD274; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DOWN-REGULATION; HIV INFECTIONS; HIV-1; HUMANS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; PROGRAMMED CELL DEATH 1 RECEPTOR; UP-REGULATION; VIRAL LOAD;

EID: 84871844273     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201108     Document Type: Article

References (44)

1. Palmer, B. E., E. Boritz, N. Blyveis, and C. C. Wilson. 2002. Discordance between frequency of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-producing CD4(+) T cells and HIV-1-specific lymphoproliferation in HIV-1-infected subjects with active viral replication. J. Virol. 76: 5925-5936. (Pubitemid 34556287)
2. Younes, S. A., B. Yassine-Diab, A. R. Dumont, M. R. Boulassel, Z. Grossman, J. P. Routy, and R. P. Sekaly. 2003. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J. Exp. Med. 198: 1909-1922. (Pubitemid 38032123)
3. Betts, M. R., M. C. Nason, S. M. West, S. C. De Rosa, S. A. Migueles, J. Abraham, M. M. Lederman, J. M. Benito, P. A. Goepfert, M. Connors, et al. 2006. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107: 4781-4789. (Pubitemid 43882629)
4. Migueles, S. A., A. C. Laborico, W. L. Shupert, M. S. Sabbaghian, R. Rabin, C. W. Hallahan, D. Van Baarle, S. Kostense, F. Miedema, M. McLaughlin, et al. 2002. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 3: 1061-1068. (Pubitemid 35363659)
5. Rosenberg, E. S., J. M. Billingsley, A. M. Caliendo, S. L. Boswell, P. E. Sax, S. A. Kalams, and B. D. Walker. 1997. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278: 1447-1450. (Pubitemid 27509814)
6. Day, C. L., D. E. Kaufmann, P. Kiepiela, J. A. Brown, E. S. Moodley, S. Reddy, E. W. Mackey, J. D. Miller, A. J. Leslie, C. DePierres, et al. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350-354. (Pubitemid 44435155)
7. D'Souza, M., A. P. Fontenot, D. G. Mack, C. Lozupone, S. Dillon, A. Meditz, C. C. Wilson, E. Connick, and B. E. Palmer. 2007. Programmed death 1 expression on HIV-specific CD4+ T cells is driven by viral replication and associated with T cell dysfunction. J. Immunol. 179: 1979-1987.
8. Trautmann, L., L. Janbazian, N. Chomont, E. A. Said, S. Gimmig, B. Bessette, M. R. Boulassel, E. Delwart, H. Sepulveda, R. S. Balderas, et al. 2006. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat. Med. 12: 1198-1202. (Pubitemid 44527357)
9. Velu, V., K. Titanji, B. Zhu, S. Husain, A. Pladevega, L. Lai, T. H. Vanderford, L. Chennareddi, G. Silvestri, G. J. Freeman, et al. 2009. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458: 206-210.
10. Akkina, R. 2012. New generation humanized mice for virus research: Comparative aspects and future prospects. Virology 435: 14-28.
11. Traggiai, E., L. Chicha, L. Mazzucchelli, L. Bronz, J. C. Piffaretti, A. Lanzavecchia, and M. G. Manz. 2004. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 304: 104-107. (Pubitemid 38451466)
12. Shultz, L. D., M. A. Brehm, S. Bavari, and D. L. Greiner. 2011. Humanized mice as a preclinical tool for infectious disease and biomedical research. Ann. N. Y. Acad. Sci. 1245: 50-54.
13. Shultz, L. D., F. Ishikawa, and D. L. Greiner. 2007. Humanized mice in translational biomedical research. Nat. Rev. Immunol. 7: 118-130. (Pubitemid 46174859)
14. -/- (RAG-hu) mouse model. Retrovirology 3: 76-89.
15. Watanabe, S., K. Terashima, S. Ohta, S. Horibata, M. Yajima, Y. Shiozawa, M. Z. Dewan, Z. Yu, M. Ito, T. Morio, et al. 2007. Hematopoietic stem cell-engrafted NOD/SCID/IL2Rgamma null mice develop human lymphoid systems and induce long-lasting HIV-1 infection with specific humoral immune responses. Blood 109: 212-218. (Pubitemid 46070123)
16. -/-) (RAG-hu) mice can sustain long-term chronic HIV-1 infection lasting more than a year. Virology 397: 100-103.
17. -/- (RAG-hu) mice. Virology 373: 342-351.
18. Brahmer, J. R., S. S. Tykodi, L. Q. Chow, W. J. Hwu, S. L. Topalian, P. Hwu, C. G. Drake, L. H. Camacho, J. Kauh, K. Odunsi, et al. 2012. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366: 2455-2465.
19. -/- mice support multilineage hematopoiesis and are susceptible to HIV-1 infection via systemic and vaginal routes. PLoS ONE 6: e20169.
20. Foreman, O., A. M. Kavirayani, S. M. Griffey, R. Reader, and L. D. Shultz. 2011. Opportunistic bacterial infections in breeding colonies of the NSG mouse strain. Vet. Pathol. 48: 495-499.
21. Joseph, A., J. H. Zheng, K. Chen, M. Dutta, C. Chen, G. Stiegler, R. Kunert, A. Follenzi, and H. Goldstein. 2010. Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody. J. Virol. 84: 6645-6653.
22. Denton, P. W., J. D. Estes, Z. Sun, F. A. Othieno, B. L. Wei, A. K. Wege, D. A. Powell, D. Payne, A. T. Haase, and J. V. Garcia. 2008. Antiretroviral preexposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med. 5: e16.
23. -/- mouse. J. Virol. 83: 8254-8258.
24. Neff, C. P., T. Kurisu, T. Ndolo, K. Fox, and R. Akkina. 2011. A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. PLoS ONE 6: e20209.
25. Denton, P. W., F. Othieno, F. Martinez-Torres, W. Zou, J. F. Krisko, E. Fleming, S. Zein, D. A. Powell, A. Wahl, Y. T. Kwak, et al. 2011. One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates. J. Virol. 85: 7582-7593.
26. Neff, C. P., T. Ndolo, A. Tandon, Y. Habu, and R. Akkina. 2010. Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model. PLoS ONE 5: e15257.
27. Brainard, D. M., E. Seung, N. Frahm, A. Cariappa, C. C. Bailey, W. K. Hart, H. S. Shin, S. F. Brooks, H. L. Knight, Q. Eichbaum, et al. 2009. Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J. Virol. 83: 7305-7321.
28. Neff, C. P., J. Zhou, L. Remling, J. Kuruvilla, J. Zhang, H. Li, D. D. Smith, P. Swiderski, J. J. Rossi, and R. Akkina. 2011. An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci. Transl. Med. 3: 66ra6.
29. Kumar, P., H. S. Ban, S. S. Kim, H. Wu, T. Pearson, D. L. Greiner, A. Laouar, J. Yao, V. Haridas, K. Habiro, et al. 2008. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 134: 577-586.
30. Barber, D. L., E. J. Wherry, D. Masopust, B. Zhu, J. P. Allison, A. H. Sharpe, G. J. Freeman, and R. Ahmed. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687. (Pubitemid 43237609)
31. Porichis, F., and D. E. Kaufmann. 2012. Role of PD-1 in HIV pathogenesis and as target for therapy. Curr. HIV/AIDS Rep. 9: 81-90.
32. Porichis, F., D. S. Kwon, J. Zupkosky, D. P. Tighe, A. McMullen, M. A. Brockman, D. F. Pavlik, M. Rodriguez-Garcia, F. Pereyra, G. J. Freeman, et al. 2011. Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood 118: 965-974.
33. McMahan, R. H., L. Golden-Mason, M. I. Nishimura, B. J. McMahon, M. Kemper, T. M. Allen, D. R. Gretch, and H. R. Rosen. 2010. Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J. Clin. Invest. 120: 4546-4557.
34. Golden-Mason, L., J. Klarquist, A. S. Wahed, and H. R. Rosen. 2008. Cutting edge: programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: racedependent differences. J. Immunol. 180: 3637-3641.
35. Aubert, R. D., A. O. Kamphorst, S. Sarkar, V. Vezys, S. J. Ha, D. L. Barber, L. Ye, A. H. Sharpe, G. J. Freeman, and R. Ahmed. 2011. Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection. Proc. Natl. Acad. Sci. USA 108: 21182-21187.
36. Kassu, A., R. A. Marcus, M. B. D'Souza, E. A. Kelly-McKnight, L. Golden- Mason, R. Akkina, A. P. Fontenot, C. C. Wilson, and B. E. Palmer. 2010. Regulation of virus-specific CD4+ T cell function by multiple costimulatory receptors during chronic HIV infection. J. Immunol. 185: 3007-3018.
37. Schacker, T. W., R. J. Bosch, K. Bennett, R. Pollard, G. K. Robbins, A. C. Collier, R. M. Gulick, J. Spritzler, and D. Mildvan; AIDS Clinical Trials Group. 2010. Measurement of naive CD4 cells reliably predicts potential for immune reconstitution in HIV. J. Acquir. Immune Defic. Syndr. 54: 59-62.
38. Muñoz-Calleja, C., A. Costantini, G. Silvestri, L. Butini, C. M. Regnery, S. Mancini, and M. Montroni. 2001. Highly active antiretroviral therapy induces specific changes in effector and central memory T cell sub-populations. AIDS 15: 1887-1890. (Pubitemid 32939254)
39. Hua, W., Y. Jiao, H. Zhang, T. Zhang, D. Chen, Y. Zhang, X. Chen, and H. Wu. 2012. Central memory CD4 cells are an early indicator of immune reconstitution in HIV/AIDS patients with anti-retroviral treatment. Immunol. Invest. 41: 1-14.
40. Clerici, M., C. Balotta, L. Meroni, E. Ferrario, C. Riva, D. Trabattoni, A. Ridolfo, M. Villa, G. M. Shearer, M. Moroni, and M. Galli. 1996. Type 1 cytokine production and low prevalence of viral isolation correlate with longterm nonprogression in HIV infection. AIDS Res. Hum. Retroviruses 12: 1053- 1061.
41. Vingert, B., D. Benati, O. Lambotte, P. de Truchis, L. Slama, P. Jeannin, M. Galperin, S. Perez-Patrigeon, F. Boufassa, W. W. Kwok, et al. 2012. HIV Controllers Maintain a Population of Highly Efficient Th1 Effector Cells in Contrast to Patients Treated in the Long Term. J. Virol. 86: 10661-10674.
42. Wherry, E. J., V. Teichgräber, T. C. Becker, D. Masopust, S. M. Kaech, R. Antia, U. H. von Andrian, and R. Ahmed. 2003. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 4: 225-234.
43. Potter, S. J., C. Lacabaratz, O. Lambotte, S. Perez-Patrigeon, B. Vingert, M. Sinet, J. H. Colle, A. Urrutia, D. Scott-Algara, F. Boufassa, et al. 2007. Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J. Virol. 81: 13904-13915. (Pubitemid 350247883)
44. Kawada, M., T. Tsukamoto, H. Yamamoto, A. Takeda, H. Igarashi, D. I. Watkins, and T. Matano. 2007. Long-term control of simian immunodeficiency virus replication with central memory CD4+ T-cell preservation after nonsterile protection by a cytotoxic T-lymphocyte-based vaccine. J. Virol. 81: 5202-5211. (Pubitemid 46744430)